

Launch Landscape Monthly Launch Tracker

July 2024 Edition

Launches through July 2024 Monthly Sales data through July 2024

Issued by The IQVIA Launch Center of Excellence (LCoE) on September 18th, 2024

© 2024. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.

The IQVIA Launch Center of Excellence (LCoE)

> Our mission: The U.S. Launch Center of Excellence at IQVIA aims to partner with our clients through the entire launch process to achieve sustainable commercial success. Through in-depth research in all facets of Launch, the LCoE provides a best-in-industry perspective on the evolving launch environment.



Brian Lasky U.S. Lead, LCoE

Brian's career spans 25+ years in pharmaceutical sales, consulting and analytics. He has expertise in commercialization, launch dynamics, and deep therapy area expertise in markets like HIV, diabetes/obesity and MASH



Ester Oben Etah, PhD Senior Principal, LCoE

Dr. Oben Etah has extensive experience in quantitative market analytics, forecasting, patient-level data, and industry analysis in Europe and the U.S.



Nadine Vangelov Senior Principal, LCoE

With over 22 years of industry experience in the U.S. and Canada, Nadine specializes in advising companies on launch strategies and tactics based on market archetypes



Nora Hannigan Associate Director, Brand Performance & Launch Solutions

With over 20 years at IQVIA, Nora has a deep knowledge of the IQVIA data assets, offering development, and thought leadership. She is an expert in launch performance assessment framework



Michael MacArthur Engagement Manager, LCoE

With over 18 years of experience in pharmaceutical finance and human data science, Michael specializes in competitive analysis, forecasting, and leveraging big data to inform strategic decision-making



Robert Unger Engagement Manager, LCoE

Rob has a background in mechanical engineering, and over 20 years of experience in the pharmaceutical industry. He specializes in custom APLD and forecasting studies



Peter Zavitsanos Senior Consultant, LCoE

Peter has over a decade of experience working in public health and healthcare data, and is responsible for publishing the Launch Landscape report each month



Elyse Muñoz, PhD Director, U.S. Research & Insights

Elyse leads a team of researchers focused on developing evidencebased perspectives on emerging healthcare trends and the strategies needed to improve outcomes for stakeholders across the system



Launch Landscape as of July 2024

There have been 33 new launches through July 2024 Infectious Disease is the top therapy area in 2024, accounting for 27% of new product launches **Top therapy areas** (share of launches) **33** new launches through July 2024 **Anti-infectives** Immunology Digestive 2024 27% 15% 12% n=33 Oncology Immunology Digestive 2023 25% 14% 11% n=84 **23** FDA Approved New Molecular Entities (NMEs) in 2024 CNS **Dermatology** Oncology 2022 There were **54** NMEs in 2023 and **36** NMEs in 2022 20% 19% 17% n=54 **Top 2022 launches** Top 2023* launches **Top 2024* launches** Monthly Sales by Launch Month (through July) by sales (USD millions) by sales (USD millions) by sales (USD millions) <u>§</u>\$700 \$644 \$7,200 ₩\$600 \$3,287 \$168 \$500 \$72 \$400 \$2,035 \$295 \$292 \$52 \$239 \$300 \$62 \$38 \$142 \$1,114 \$200 \$104 \$143 \$15 \$100 \$52 \$105 \$638 \$304 \$0 2022 (n=32) 2023 (n=41) 2024 (n=33) MOUNJARO **OPDUALAG** VABYSMO ZEPBOUND AREXVY ABRYSVO OCTAGAM CABTREO FLUAD Jan: Months 1-7 Feb: Months 1-6 Mar: Months 1-5 (Jun-22) (Feb-22) (Mar-22) (Dec-23) (Jul-23) (Jul-23) (Jan-24) Feb-24) (Jul-24) Apr: Months 1-4 May: Months 1-3 Jun: Months 1-2 RSV RSV Type 2 Diabetes Wet AMD cITP Acne Melanoma Obesity Flu Vaccine Vaccine Vaccine Jul: Month 1


*First year sales from launch month through July 2024

Notes: All sales values are USD. cITP = Chronic immune thrombocytopenic purpura; CNS = Central nervous system; NME = new molecular entity IQVIA U.S. Launch Landscape Tracker, July 2024


There have been 33 new launches through July 2024, tracking closely with prior years

2023 closed with 84 total launches, surpassing the 54 launches in 2022

Time-aligned cumulative launches 2022–Jul 2024



Source: National Sales Perspective; Launch Center of Excellence, IQVIA; publicly available information from the FDA Notes: CNS = Central nervous system




Share of launches by therapy area

IQVIA U.S. Launch Landscape Tracker, July 2024


/∃IOVIA

Through July, Infectious Disease and Dermatology products account for 30% of 2024 launches and 63% of 2024 sales

Share of launches by therapy area 2022–Jul 2024



Share of sales by therapy area 2022–Jul 2024




Source: National Sales Perspective; Launch Center of Excellence, IQVIA; publicly available information from the FDA Notes: CNS = Central nervous system; RSV = Respiratory Syncytial Virus IQVIA U.S. Launch Landscape Tracker, July 2024



2024 sales are led by Pfizer's Octagam for chronic immune thrombocytopenic purpura (cITP)

2024 – 33 Launches



Source: National Sales Perspective; Launch Center of Excellence, IQVIA Notes: All sales values are USD. cITP = chronic immune thrombocytopenic purpura; ES-SCLC = Extensive-stage small cell lung cancer hATTR-PN = hereditary transthyretin amyloidosis; NASH = Nonalcoholic steatohepatitis 2024 – Top 10 Performers

Product	Company	Indication	Launch date	First year gross sales (as of Jul-24)
Octagam Immune globulin (IV)	Pfizer	Chronic immune thrombocytopenic purpura (cITP)	Jan-24	\$71.8M
Cabtreo clindamycin phosphate, adapalene & benzoyl peroxide	Bausch Health	Acne	Feb-24	\$51.8M
Fluad Influenza Vaccine	CSL Seqirus	Influenza vaccine ages 65+	Jul-24	\$37.8M
Balfaxar prothrombin complex concentrate, human-lans	Octapharma	Reversal of warfarin-induced acquired coagulation factor deficiency	Jan-24	\$28.7M
Wainua eplontersen	AstraZeneca	Polyneuropathy from hereditary transthyretin amyloidosis (hATTR-PN)	Jan-24	\$25.0M
Vevye cyclosporine	Harrow Eye	Dry eye disease	Jan-24	\$15.6M
Flucelvax Influenza vaccine	CSL Seqirus	Influenza vaccine ages 6+ months	Jul-24	\$14.8M
Imdelitra tarlatamab-dlle	Amgen	Extensive-stage small cell lung cancer (ES-SCLC)	May-24	\$11.9M
Rezdiffra resmetirom tablets	Madrigal	Nonalcoholic steatohepatitis (NASH)	Apr-24	\$9.0M
Zymfentra antihemophilic factor recombinant	Celltrion	Maintenance of UC following IV infliximab	Mar-24	\$3.5M

IQVIA U.S. Launch Landscape Tracker, July 2024



Having surpassed \$3B in sales in July 2024, Lilly's Zepbound for obesity leads 2023's 2nd highest performer, Arexvy, by over \$1B



Source: National Sales Perspective; Launch Center of Excellence, IQVIA

Notes: All sales values are USD. AMD = Age-related macular degeneration; CD = Crohn's disease; LRTD = lower respiratory tract disease; PsA = psoriatic arthritis; PsO = plaque psoriasis; RA = rheumatoid arthritis; UC = ulcerative colitis; v/o = vears old


OC = uicerative contis, y/o = years of

IQVIA U.S. Launch Landscape Tracker, July 2024



6

Lilly's Mounjaro was the top selling product of 2022, followed by Genentech's Vabysmo for wet macular degeneration



Source: National Sales Perspective; Launch Center of Excellence, IQVIA

Notes: All sales values are USD. As of June 2024, All COVID-19 Vaccinations launched in 2022 have been removed due to emergency authorization expiration

IQVIA U.S. Launch Landscape Tracker, July 2024

2022 – Top 10 Performers






Market Spotlight: Obesity and Diabetes

Wegovy is having success from its recent March 2024 approval in cardiovascular risk reduction

In late August, Lilly revealed significant findings from the SURMOUNT-1 study, where tirzepatide reduced the risk of obese pre-diabetics progressing to type 2 diabetes by 94% versus placebo




Source: National Sales Perspective, National Prescription Audit, Patient Insights; Launch Center of Excellence, IQVIA



From a sales perspective, Lilly's Zepbound is having a similar year-one trajectory to its predecessor, Mounjaro

Despite shortages, Mounjaro and Zepbound sales continue to exceed Ozempic and Wegovy during the same launch timeframe



Source: IQVIA SMART, Launch Edition, National Sales Perspective; Launch Center of Excellence, IQVIA

